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FEV1 = forced expiratory volume in 1 second; GCR = glucocorticoid receptor; IL = interleukin; IL-4R = interleukin-4 receptor; IRS = insulin receptor
substrate; rhuIL-4R = soluble recombinant human interleukin-4 receptor; Stat = signal transducer and activator of transcription; VCAM = vascular
cell adhesion molecule.
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Introduction
Interleukin (IL)-4 is a key cytokine in the development of
allergic inflammation. It is associated with induction of the
e isotype switch and secretion of IgE by B lymphocytes
[1]. IgE-mediated immune responses are further enhanced
by IL-4 through its ability to upregulate IgE receptors on
the cell surface: the low-affinity IgE receptor (FceRII;
CD23) on B lymphocytes and mononuclear phagocytic
cells and the high-affinity IgE receptor (FceRI) on mast
cells and basophils [2]. IgE-dependent mast cell activation
induced by IL-4 has a pivotal role in the development of
immediate allergic reactions. An additional mechanism by
which IL-4 contributes to airway obstruction in asthma is
through the induction of mucin gene expression and the
hypersecretion of mucus [3]. IL-4 increases the expression
of eotaxin and other inflammatory cytokines from fibro-
blasts that might contribute to inflammation and lung
remodelling in chronic asthma [4].
An important activity of IL-4 in promoting cellular inflamma-
tion in the asthmatic lung is the induction of vascular cell
adhesion molecule (VCAM)-1 on vascular endothelium [5].
Through the interaction of VCAM-1, IL-4 is able to direct
the migration of T lymphocytes, monocytes, basophils, and
eosinophils to inflammatory loci. In addition, IL-4 inhibits
eosinophil apoptosis and promotes eosinophilic inflamma-
tion by inducing eosinophil chemotaxis and activation
through the increased expression of eotaxin [6].
An essential biological activity of IL-4 in the development
of allergic inflammation is the ability to drive the differentia-
tion of naive T helper type 0 (TH0) lymphocytes into TH2
lymphocytes [7,8]. These TH2 cells are able to secrete IL-4,
IL-5, IL-9 and IL-13 but lose the ability to produce interferon-
g [9]. Using human cells, administration of IL-4 generates
TH2-like lymphocyte clones, whereas incubation with anti-
IL-4 blocks this differentiation. The induction of TH2-like
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lymphocytes is a unique biological activity of IL-4 because
IL-4 receptors and not IL-13 receptors are expressed on T
cells [10]. IgE production and the induction of VCAM-1 are
activities shared with the related cytokine IL-13.
In addition to driving the differentiation of TH0 lymphocytes
into the TH2 phenotype, IL-4 is important in allergic immune
responses owing to its ability to prevent apoptosis of T lym-
phocytes. Activation of these cells results in rapid prolifera-
tion and secretion of cytokines. In the absence of an
appropriate signal, activated T helper lymphocytes rapidly
become apoptotic and are eliminated. Several cytokines,
including IL-2, IL-4, IL-7, and IL-15, are effective in prevent-
ing the death of activated T cells. Of these, IL-4 and IL-15
are the most effective [11]. Inhibition of apoptosis by IL-4
might be mediated partly by the ability of this cytokine to
maintain levels of the survival-promoting protein Bcl-2 in T
cells [11]. Apoptosis of T lymphocytes can be induced
through signals mediated by Fas ligand through the Fas
(CD95) receptor expressed on these cells. T cells from
asthmatic lungs show defective expression of Fas. Co-cul-
turing of T cells with IL-4 downregulates Fas expression on
the cell surface. The expression of IL-4 in the asthmatic
lung and the secondary lack of Fas expression might
explain the persistence of inflammatory cellular infiltrates in
allergic asthma. Apoptosis of TH2 lymphocytes (and possi-
bly eosinophils) could represent a pathway by which IL-4
blockade produces rapid clinical benefits in asthma. Corti-
costeroids normally cause apoptosis in mature T helper cell
lines. Induction of cell death is prevented by IL-2 in TH1
cells and by IL-4 in TH2 cells [12]. IL-4 and IL-2 synergize
to render lymphocytes refractory to the anti-inflammatory
influences of corticosteroids. This is a result of alternative
splicing of the glucocorticoid receptor (GCR) mRNA, gen-
erating GCR-b. GCR-b is unable to bind glucocorticoids
but can bind and antagonize the transactivating activity of
the classic GCR-a. Through these mechanisms, the
autocrine production of IL-4 by TH2 cells in the asthmatic
lung might render these cells refractory to the beneficial
influences of corticosteroids [13]. Synergistic benefits of
interleukin-4 receptor (IL-4R) with inhaled corticosteroids
can be expected in asthmatic patients.
Clinical observations of IL-4 in allergic
disease
IL-4 is increased in the serum and bronchoalveolar lavage
of allergic individuals [14,15], and peripheral blood
mononuclear cells from atopic asthmatics increase IL-4
production in response to dust mite antigen [16]. Nebu-
lized administration of IL-4 to patients with mild asthma
resulted in a significant increase in airway hyper-
responsiveness that was associated with the elevation of
sputum eosinophil numbers [17]. A variety of findings
suggest that atopic individuals have altered regulation in
their IL-4 production. In response to bacterial antigens,
CD4+ T cell clones from atopics produce IL-4 and IL-5,
whereas non-atopic CD4+ T cell clones produce TH1
cytokines [18]. Atopic subjects have a higher frequency of
IL-4-producing T cells than do normal subjects [19], and T
cell clones generated from cord blood lymphocytes of
newborns with atopic parents produce higher IL-4 con-
centrations than neonatal lymphocytes of newborns with
non-atopic parents [20].
IL-4 genetics and asthma
Asthma has been linked to chromosome 5q31–33
through genome searches and screening of candidate
genes [21,22]. This locus includes the genes for the TH2
cytokines IL-4, IL-5, IL-9, and IL-13. Aberrant production of
IL-4 or hyperresponsiveness to this cytokine owing to
inherited defects might further contribute to the patho-
physiology of asthma. Optimal signaling by IL-4 (reviewed
in [23]) involves its interaction with receptors consisting of
a heterodimer of high-affinity IL-4Ra and either the
common  g chain or the IL-13 receptor a chain. Binding of
IL-4 results in the tyrosine phosphorylation of signal trans-
duction molecules including motifs similar to those
involved in insulin signaling, the insulin receptor substrate
(IRS)-1, IRS2 and signal transducer and activator of tran-
scription (Stat)-6 [23]. IRS1 and IRS2 regulate prolifera-
tion and protection from apoptosis. Stat-6 is necessary for
IL-4-dependent expression of CD23, MHC class II, e
heavy chain, and IL-4Ra [23] and, as noted, is essential
for the differentiation of TH2 lymphocytes. BCL6 is a
protein that counteracts the stimulatory effects of Stat-6
by binding to Stat-6 responsive promoter elements and
repressing transcription. Through this mechanism, BCL6
has been shown to suppress IL-4-induced IgE production
[24]. Asthma has been genetically linked to polymor-
phisms in the genes encoding IL-4Ra, IL-13Ra, Stat-6,
and BCL6. A summary of the naturally occurring polymor-
phisms that are linked to atopy and asthma and might
influence IL-4 production or IL-4 signaling is given in
Table 1. Individuals genetically programmed to be hyper-
responsive to IL-4 represent a cohort of subjects who
might be therapeutically responsive to an IL-4 antagonist.
Animal studies demonstrating the role of IL-4
in asthma
Neutralizing IL-4 with anti-IL-4 antibodies in mice inhibits
the development of allergen-specific IgE [25], and reduces
eosinophilic inflammation [25] and airway reactivity [26].
These results have been confirmed by using IL-4 knockout
mice. In addition to these effects, recombinant soluble IL-4
receptor, which acts as a decoy for IL-4 binding and neu-
tralizes IL-4 activity, has been shown in murine models to
block allergen-induced airway hyperreactivity [27] and to
inhibit VCAM-1 expression, eosinophil influx, and excessive
production of mucus [28]. By inhibiting TH2-like lympho-
cyte differentiation and promoting the apoptosis of estab-
lished TH2-like cells, IL-4 blockade inhibits the biological
activities of IL-4 and, equally important, reduces theRespiratory Research    Vol 2 No 2 Steinke and Borish
production of IL-5. Nonetheless, mice deficient in IL-4 (IL-4
knockouts) maintain residual TH2 responses, which might
explain the persistent low-level expression of IL-5,
eosinophilia, and airway hyperreactivity observed in some
of these murine studies [10]. Although there is always a
danger in over-interpreting data derived from animal
models, these observations support the role of IL-4 in
asthma and allergic disorders.
Soluble cytokine receptors as therapeutic
agents
The IL-4R is a cell-surface, heterodimeric complex consist-
ing of a specific, high-affinity a chain (IL-4Ra) and a second
chain that can be either the common g chain or the a chain
of the IL-13 receptor (IL-13Ra) [23]. The common g chain is
found in multiple cytokine receptors. Although both chains
of the heterodimer are required to mediate cellular activa-
tion, only IL-4Ra is necessary for binding IL-4. Secreted
forms of IL-4Ra occur naturally and are expressed in allergic
inflammation [29]. Soluble IL-4R is capable of interacting
with IL-4 even though it lacks the transmembrane and cyto-
plasmic domains. Because it does not induce cellular acti-
vation but instead binds and sequesters IL-4, soluble IL-4R
serves as an anti-inflammatory mechanism that can counter
the effects of IL-4 (Fig. 1) and might represent an endoge-
nous autoregulatory or homeostatic mechanism. Acting as a
decoy to bind and neutralize circulating cytokine, coupled
with the high specificity and high affinity of binding for the
cytokine, makes the soluble receptor ideal as a cytokine
antagonist. Soluble recombinant human IL-4 receptor
(rhuIL-4R; Nuvance™; Immunex) is the extracellular portion
of human IL-4Ra, the gene encoding which has been
cloned and its product expressed in a mammalian expres-
sion system. Because the amino acid and carbohydrate or
glycosylation sequences are identical to those of human
IL-4R, soluble receptors are relatively nonimmunogenic. This
is in contrast to chimerized or humanized monoclonal anti-
bodies, which retain some murine sequences, or IL-4
muteins that are not authentic. The soluble tumor necrosis
factor receptor, EnbrelÒ, has been demonstrated to be safe
and highly effective for the long-term treatment of rheuma-
toid arthritis in adults and children.
Clinical studies with rhuIL-4R (Nuvance™)
The promising results in preclinical studies led to prelimi-
nary investigations in which rhuIL-4R proved safe and
effective in the treatment of patients with asthma [30,31].
In the phase I study, subjects with mild or moderate per-
sistent asthma were withdrawn from their inhaled corticos-
teroids and randomly assigned to receive placebo or
rhuIL-4R at 0.5 or 1.5 mg by nebulizer [30]. There were no
significant adverse events related to the study drug and no
patients developed antibodies against rhuIL-4R. Pharma-
cokinetic analysis demonstrated a prolonged serum half-
life of about 5 days, suggesting that weekly therapy would
be effective. After acute discontinuation of inhaled corti-
costeroids, no subject in the rhuIL-4R 1.5 mg group with-
drew for asthma exacerbations, compared with three of
eight in the rhuIL-4R 0.5 mg group and two of eight in the
placebo group. Treatment with 1.5 mg of rhuIL-4R was
associated with significantly better forced expiratory
volume in 1 s (FEV1) at 2 h after treatment and on days 2,
4, and 15 (P < 0.05). Statistically significant differences in
asthma symptom score (P < 0.05) and b2-agonist use
(P < 0.05) were associated with treatment with rhuIL-4R.
Scores on the third section of the AQLQ (Asthma Quality
of Life Questionnaire, showing a patient’s perception of
general health and physical functioning) worsened in the
placebo group and improved in the rhuIL-4R 1.5 mg group
(P < 0.05). Methacholine testing showed decreased
sensitivity in six out of eight patients tested in the 1.5 mg
group. Exhaled nitric oxide scores were significantly
improved in patients receiving rhuIL-4R (P < 0.05), which
is consistent with an anti-inflammatory effect.
Table 1
Genes associated with IL-4 and IL-4 signaling linked to asthma and allergies
Gene Polymorphism Location Reference
Interleukin-4 promoter A®G –81 [32]
C®T –285 [32]
C®T –590 [33]
Interleukin-4 receptor, a chain Ile®Val +50 [34]
Arg®Gln +551 [35]
Ser®Pro +503 [36]
Interleukin-13 receptor, a chain A®G +1398 [37]
Stat-6 G®A +2964 (3¢ UTR) [38]
BCL6 HindIII 5¢ untranslated region [39]In the phase I/II double-blind, placebo-controlled study, 62
moderate persistent asthmatic patients were randomized
to 12 weekly nebulizations of 0.75, 1.5, or 3.0 mg of rhuIL-
4R (Nuvance™) or placebo [31]. Before the study, patients
documented their dependence on inhaled corticosteroids
by an exacerbation in asthma induced by one or two 50%
reductions in inhaled corticosteroid dose at 2-week inter-
vals. After being restabilized on inhaled corticosteroids for
2 weeks, the inhaled corticosteroids were discontinued at
the time that study medication was begun. IL-4R was safe
and well tolerated. Antibodies against rhuIL-4R occurred in
one patient that were non-neutralizing and resulted in no
symptoms. Efficacy was demonstrated by a significant
decline in FEV1 observed in the placebo group (–0.35 l;
–13% predicted) which did not occur in the 3.0 mg treat-
ment group (–0.09 l; –2% predicted; P = 0.053 over the
three-month treatment period). Daily patient-measured
morning FEV1 also demonstrated a significant decline in
the placebo group (–0.5 l; –18% predicted) that did not
occur in the 3.0 mg treatment group (–0.1 l; P = 0.02 over
the three-month treatment period; –4% predicted). The
afternoon FEV1 also improved at the highest dose and was
19% better than placebo. The efficacy of rhuIL-4R was
further confirmed by the absence of an increase in asthma
symptom score (a change of 0.1) in the 3.0 mg treatment
group in comparison with the placebo group (a change of
1.4 over one month; P = 0.075).
Conclusions
These studies demonstrate that IL-4R is a potentially safe
and effective new treatment for asthma without the use of
corticosteroids. Dosing once a week, with an inhaled med-
ication targeting the lungs, will probably improve patient
compliance, which is one of the greatest challenges to the
effective treatment of asthma. Inhibiting inflammation at a
key regulatory point, IL-4R might affect the long-term
disease progression in asthma. IL-4R should also be effec-
tive in patients with non-allergic forms of asthma. Although
these patients do not demonstrate allergen-specific IgE, the
presence of eosinophilic inflammation and elevated total IgE
suggests the differentiation of TH2-like lymphocytes, which
are responsible for the production of IL-5 and other
cytokines that promote the development of eosinophilia. On
the basis of our current knowledge of the differentiation of
IL-5-producing TH2-like lymphocytes, this process is IL-4-
dependent and should be susceptible to suppression by IL-
4R therapy. Other atopic disorders such as allergic rhinitis
and atopic dermatitis are thought to be mediated by IL-4
and might also respond to IL-4 blockade with IL-4R therapy.
Soluble IL-4 receptor studies are continuing and this class
of drugs represents the next generation of asthma therapy.
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Figure 1
IL-4 binding to cellular IL-4R and its inhibition by soluble IL-4R (sIL-4R). (a) IL-4 binds to cellular IL-4R, mediating cellular activation and important
pro-inflammatory functions in asthma. For clarity, only the IL-4Ra chain of the heterodimer is shown, represented by three domains: extracellular
(green), transmembrane (white) and cytoplasmic (red). It should be noted, however, that both chains of the heterodimer are required to initiate
intracellular signaling. (b) The sIL-4R consists of the extracellular portion of IL-4Ra. It retains the ability to bind IL-4 with high affinity and high
specificity and thereby functions as a decoy receptor which can sequester naturally occurring IL-4 and prevent it from activating the cell. sIL-4R
cannot activate cellular signaling; thus, it serves as an anti-inflammatory agent that can counter the effects of IL-4 in asthma.
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